Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.

NCT00987935 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00987935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00987935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
January 31, 2016
Enrollment
134 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular